Keymed Biosciences Inc. 2162.HK Stock
Keymed Biosciences Inc. Price Chart
Keymed Biosciences Inc. 2162.HK Financial and Trading Overview
| Keymed Biosciences Inc. stock price | 31.2 HKD |
| Previous Close | 41.55 HKD |
| Open | 42 HKD |
| Bid | 45.25 HKD x N/A |
| Ask | 45.3 HKD x N/A |
| Day's Range | 42 - 47.1 HKD |
| 52 Week Range | 27.4 - 82.85 HKD |
| Volume | 2.57M HKD |
| Avg. Volume | 1.74M HKD |
| Market Cap | 12.67B HKD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.49 HKD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.44 HKD |
2162.HK Valuation Measures
| Enterprise Value | 8.47B HKD |
| Trailing P/E | N/A |
| Forward P/E | -20.590908 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 126.640625 |
| Price/Book (mrq) | 3.7618337 |
| Enterprise Value/Revenue | 84.659 |
| Enterprise Value/EBITDA | -16.222 |
Trading Information
Keymed Biosciences Inc. Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 41.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 82.85 HKD |
| 52 Week Low | 27.4 HKD |
| 50-Day Moving Average | 55.91 HKD |
| 200-Day Moving Average | 53.18 HKD |
2162.HK Share Statistics
| Avg. Volume (3 month) | 1.74M HKD |
| Avg. Daily Volume (10-Days) | 1.19M HKD |
| Shares Outstanding | 279.74M |
| Float | 183.07M |
| Short Ratio | N/A |
| % Held by Insiders | 28.37% |
| % Held by Institutions | 17.87% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -544.14% |
| Gross Margin | 97.41% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -8.65% |
| Return on Equity (ttm) | -8.69% |
Income Statement
| Revenue (ttm) | 100.06M HKD |
| Revenue Per Share (ttm) | 0.38 HKD |
| Quarterly Revenue Growth (yoy) | -99.90% |
| Gross Profit (ttm) | 97.48M HKD |
| EBITDA | -522216992 HKD |
| Net Income Avi to Common (ttm) | -308115008 HKD |
| Diluted EPS (ttm) | -1.31 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.18B HKD |
| Total Cash Per Share (mrq) | 11.45 HKD |
| Total Debt (mrq) | 122.19M HKD |
| Total Debt/Equity (mrq) | 3.66 HKD |
| Current Ratio (mrq) | 8.717 |
| Book Value Per Share (mrq) | 12.042 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -401934016 HKD |
| Levered Free Cash Flow (ttm) | -410145760 HKD |
Profile of Keymed Biosciences Inc.
| Country | Hong Kong |
| State | N/A |
| City | Chengdu |
| Address | Building D2 |
| ZIP | 610219 |
| Phone | 86 28 8861 0620 |
| Website | https://www.keymedbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 613 |
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
Q&A For Keymed Biosciences Inc. Stock
What is a current 2162.HK stock price?
Keymed Biosciences Inc. 2162.HK stock price today per share is 31.2 HKD.
How to purchase Keymed Biosciences Inc. stock?
You can buy 2162.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Keymed Biosciences Inc.?
The stock symbol or ticker of Keymed Biosciences Inc. is 2162.HK.
Which industry does the Keymed Biosciences Inc. company belong to?
The Keymed Biosciences Inc. industry is Biotechnology.
How many shares does Keymed Biosciences Inc. have in circulation?
The max supply of Keymed Biosciences Inc. shares is 276.7M.
What is Keymed Biosciences Inc. Price to Earnings Ratio (PE Ratio)?
Keymed Biosciences Inc. PE Ratio is now.
What was Keymed Biosciences Inc. earnings per share over the trailing 12 months (TTM)?
Keymed Biosciences Inc. EPS is -1.49 HKD over the trailing 12 months.
Which sector does the Keymed Biosciences Inc. company belong to?
The Keymed Biosciences Inc. sector is Healthcare.